PetVivo Holdings

PetVivo Holdings, Inc. is a veterinary biotech and biomedical device company. It is engaged in the business of translating or adapting human biotech and medical technology into products for commercialization in the veterinary market to treat companion animals such as dogs, horses, cats, and other animals suffering from osteoarthritis and other afflictions. The firm's lead product includes Kush, is an intra-articular injection comprised of patented, gel-like biomaterials that is being commercialized for companion animal osteoarthritis. The company was founded by John Lai and John F. Dolan on March 31, 2009 and is headquartered in Minneapolis, MN.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

PetVivo Holdings reports strong Q1 earnings, eyes market expansion

PetVivo Holdings demonstrated robust financial and operational progress in Q1 2025, driven by strong revenue growth and efficient cost management.
The company's focus on expanding market reach, accelerating Spryng adoption, and enhancing sales and marketing teams positions it for future growth.
While challenges like narrowing net loss persist, PetVivo's strategic initiatives and favorable financial position offer opportunities for sustained success.

PetVivo reports strong Q2 growth, eyes expansion in animal health

PetVivo Holdings delivered impressive financial and operational results in Q2 2025, marked by substantial revenue growth and improved net loss.
With a focus on expanding its distribution network, strategic partnerships, and clinical trials, PetVivo is poised for continued growth and market expansion.
While challenges in scaling operations and maintaining quality exist, the company's commitment to growth and innovation presents significant opportunities for success in the animal health market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PetVivo Holdings, Inc. is a veterinary biotech and biomedical device company, which engages in the business of licensing and commercializing medical devices and biomaterials for the treatment and management of afflictions and diseases in animals, initially for dogs and horses. The firm's lead product includes Spryng with OsteoCushion Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses. The company was founded by John Lai and John F. Dolan on March 31, 2009 and is headquartered in Edina, MN.

Minneapolis, Minnesota--(Newsfile Corp. - January 11, 2024) - PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW), a company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals, will be participating in The Microcap Conference, which will take place January 30, 31, February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ. John Lai, Chief Executive Officer, will be presenting on January 31 & February 1, 2024.

PetVivo Holdings, Inc. Invites You to Join Us at The Microcap Conference

MINNEAPOLIS, Jan. 09, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals today announced it will be exhibiting at the Veterinary Meeting & Expo Conference from January 14th to January 17th, 2024, at the Orange County Convention Center in Orlando, FL.

PETVIVO HOLDINGS, INC. TO EXHIBIT AT VETERINARY MEETING AND EXPO CONFERENCE IN ORLANDO, FLORIDA

New York, December 22, 2023 – PetVivo Holdings, Inc. (Nasdaq: PETV) has achieved a distribution milestone, reporting a total of 4500 syringes of Spryng™ with OsteoCushion™ technology distributed to veterinarians in the 2023 calendar year. Spryng, the company's signature product, helps to manage lameness, joint pain and osteoarthritis in horses and small animals.

PRISM Analysis: PetVivo Holdings Achieves Distribution Milestone; Shares Soar 40%

MINNEAPOLIS, Dec. 22, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for equine and companion animals, announced today it has entered into a definitive distribution agreement with Covetrus North America, LLC (“Covetrus”). Covetrus will inventory, market and promote PetVivo's veterinary medical device, Spryng™ with OsteoCushion™ technology, throughout the United States. Covetrus sales and marketing activities will commence on January 1, 2024.

PETVIVO HOLDING, INC. ANNOUNCES DISTRIBUTION AGREEMENT WITH COVETRUS NORTH AMERICA, LLC

MINNEAPOLIS, MN, US, Dec. 21, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, achieved a significant milestone – surpassing 4500 syringes of Spryng™ with OsteoCushion™ technology distributed to veterinarians in the 2023 calendar year. Thanks to the support of veterinarians throughout the United States, Spryng has experienced strong momentum this year, driven by the beneficial outcomes experienced by thousands of animals injected with this life changing product.

PetVivo Holdings, Inc. Achieves Distribution Milestone Surpassing 4500 Syringes of Spryng™ in 2023

MINNEAPOLIS, MN, US, Dec. 11, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, achieved a significant milestone – the sale of its signature product Spryng™ with OsteoCushion™ Technology to more than 600 veterinary clinics in 49 states.

PetVivo Holdings, Inc. Achieves National Distribution of Spryng™ to More than 600 Veterinary Clinics in 49 States

MINNEAPOLIS, MN, US, Nov. 21, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced today it will be exhibiting at the American Association Equine Practitioners (“AAEP”) conference to be held November 29th to December 2nd, 2023 at the San Diego Convention Center in San Diego, California.

PetVivo Holdings, Inc. to Exhibit at American Association of Equine Practitioners Conference in San Diego, California

PetVivo Holdings, Inc. (NASDAQ:PETV ) Q2 2024 Earnings Conference Call November 14, 2023 5:00 PM ET Company Participants John Dolan - Chief Business Development Officer & General Counsel John Lai - Chief Executive Officer & President Bob Folkes - Chief Financial Officer Conference Call Participants Operator Welcome, everyone, to the PetVivo Holdings, Inc., 2024 Fiscal Year Second Quarter Earnings Report. This is November 14, 2023, and I will now hand over to Mr.

PetVivo Holdings, Inc. (PETV) Q2 2024 Earnings Call Transcript

Conference call begins at 4:00 p.m. Central time today EDINA, MN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended September 30, 2023 (“second quarter of 2024”).

PetVivo Reports Second Quarter of Fiscal 2024 Financial Results

MINNEAPOLIS, MN, US, Nov. 09, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Tuesday, November 14, 2023 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day.

PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2023

MINNEAPOLIS, MN, US, Oct. 12, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that the Company will be releasing the results of a clinical study conducted by Ethos Veterinary Health at the American College of Veterinary Surgeons (“ACVS”) annual conference on the completion of a clinical study, which examined the benefit and tolerability of an intra-articular injection of a collagen-elastin biomaterial (i.e. Spryng™ with OsteoCushion™ Technology) into the stifle joint of dogs with suspected cruciate ligament rupture. Dr. Erik Kleeman, DVM will be presenting the poster at ACVS.

PetVivo Holdings, Inc. Announces Presentation of Clinical Study Results at the American College of Veterinary Surgeons Conference in Louisville, Kentucky

Minneapolis, Minnesota--(Newsfile Corp. - October 9, 2023) -  PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced today it will be participating in The ThinkEquity Conference, which will take place on October 19, 2023 at The Mandarin Oriental Hotel in New York. John Lai, Chief Executive Officer of PetVivo Holdings, Inc. will be presenting in the South Salon II of the Mandarin Oriental Hotel from 3:00 PM to 3:30 PM EDT on October 19th.

PetVivo Holdings Inc. Announces Participation in The ThinkEquity Conference

MINNEAPOLIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for pets, is pleased to announce it will be featured as a presenting company at the H.C. Wainwright 25th Annual Global Investment Conference. H.C. Wainwright & Co. is hosting its 25th Annual Global Investment Conference, which is being held on September 11 to 13, 2023.

PETVIVO HOLDINGS, INC. ANNOUNCES PARTICIPATION AT THE H.C.

MINNEAPOLIS, MN, US, Aug. 28, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, achieved a significant milestone – the sale of its signature product Spryng™ with OsteoCushion™ Technology to more than 500 veterinary clinics in 49 states.

PetVivo Holdings, Inc. Achieves National Distribution of Spryng to More than 500 Veterinary Clinics in 49 States

PetVivo Holdings, Inc. (NASDAQ:PETV ) Q1 2024 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants John Dolan - Chief Business Development Officer & General Counsel John Lai - CEO, President, & Director Bob Folkes - CFO Conference Call Participants Operator All right. Welcome, everyone, to the PetVivo Holdings, Inc., 2024 Fiscal Year First Quarter Earnings Report.

PetVivo Holdings, Inc. (PETV) Q1 2024 Earnings Call Transcript

Conference call begins at 4:00 p.m. Central time today EDINA, MN, Aug. 10, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV and PETVW ), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended June 30, 2023 (“first quarter of 2024”).

PetVivo Reports First Quarter of Fiscal 2024 Financial Results

MINNEAPOLIS, MN, US, Aug. 07, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Thursday, August 10, 2023 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day.

PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE FIRST QUARTER ENDED June 3, 2023

MINNEAPOLIS, MN, US, July 20, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is fastly approaching a remarkable milestone – the sale of its signature product Spryng™ with OsteoCushion™ to its 500th veterinary clinic. PetVivo has supplied this life enhancing product for companion animals to more than 450 clinics in 47 states.

PetVivo Holdings, Inc. Achieves National Distribution of Spryng to More than 450 Veterinary Clinics

MINNEAPOLIS, MN, US, June 29, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for companion animals, announced it has rescheduled its earnings conference call for the year ending March 31, 2023. The call will now be held on Friday, June 30, 2023 at 10:00 AM ET (9:00 AM CT).

PETVIVO HOLDINGS, INC. ANNOUNCES RESCHEDULED EARNINGS CALL FOR THE YEAR ENDED MARCH 31, 2023

Conference call begins at 4:00 p.m. Central time today EDINA, MN, June 29, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for its fiscal year ended March 31, 2023 (“fiscal 2023”).

PetVivo Reports Fiscal 2023 Full Year Financial Results

Developmental biomedical device company PetVivo Holdings Inc. OTCMKTS: PETV makes pet medical devices and therapeutics. What kind of medical devices would pets need?

PetVivo Sales Spryng Higher on Injectable OA Relief for Pets

MINNEAPOLIS, MN, US, June 27, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Dr. Jeremy Caplin has accepted a position with the Company as its new Research Director.

Dr. Jeremy Caplin Joins PetVivo Holdings, Inc. as the Director of Research

MINNEAPOLIS, MN, US, June 26, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for companion animals, will report financial results for the year ending March 31, 2023, on Thursday, June 29, 2023 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day.

PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE YEAR 2023 ENDED MARCH 31, 2023

MINNEAPOLIS, June 21, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo" or the “Company) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and equine announced today it has received an initial regulatory assessment from a Contract Research Organization outlining pathways to regulatory approval of various indications for its proprietary Biomatrix Particulate Technology. The regulatory assessment will assist the Company in better understanding the regulatory pathway to approval of one or more human products such as dermal fillers, tendon and ligament repair, intraarticular injectable devices, urinary incontinence bulking agents and dental – soft tissue augmentation biomaterials.

PetVivo Holdings, Inc. Begins Process to Pursue Approval of Biomatrix Particulate Technology for Initial Human Indication

MINNEAPOLIS, MN, US, June 05, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Dr. Thomas Yarbrough has accepted a position with the Company as its new Senior Research Director.

News for PetVivo Holdings Stock (PETV)